{"version":"1.0","type":"rich","provider_name":"Acast","provider_url":"https://acast.com","height":250,"width":700,"html":"<iframe src=\"https://embed.acast.com/$/6388909dcb17a60010c40c56/65781ec978e0250017aad566?\" frameBorder=\"0\" width=\"700\" height=\"250\"></iframe>","title":"Vicore Pharma: Restoring lung function for IPF patients","description":"<p>Hear Vicore Pharma’s CEO, Ahmed Mousa speak to Optimum's Richard Staines on their new treatment for Idiopathic Pulmonary Fibrosis&nbsp;(IPF), C21. It aims to improve available treatments for patients of IPF by halting the progression of fibrosis and has the aim of restoring lung function.</p><p><br></p>","author_name":"Optimum Strategic Communications"}